Phase 1/2 study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in relapsed/refractory AML

Poster Presentation | Jun 12, 2026

Author

Cuglievan B, et al.

Congress

European Hematology Association Annual Congress 2026

Stockholm, Sweden | June 11 – 14, 2026